Overview

Glucokinase Activator in Monogenic Diabetes

Status:
NOT_YET_RECRUITING

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

Evaluating a novel, allosteric glucokinase activator in monogenic diabetes secondary to inactivating glucokinase mutations: a randomised, cross-over trial

Phase:

PHASE2

Details

Lead Sponsor:

Chinese University of Hong Kong

Treatments:

Dorzagliatin